瑞巴派特保留灌肠治疗溃疡性结肠炎疗效观察  

Clinical efficacy of rebamipide enemas treatment for patients with ulcerative colitis

作　　者：李千迅[1] 张雷[1] 

机构地区：[1]吉林省人民医院,长春130021

出　　处：《中国实用医药》2008年第14期16-18,共3页China Practical Medicine

摘　　要：目的观察瑞巴派特保留灌肠联合5-氨基水杨酸口服对溃疡性结肠炎的疗效。方法128例患者随机分为瑞巴派特治疗组、思密达治疗组和对照组。瑞巴派特治疗组应用瑞巴派特保留灌肠联合5-氨基水杨酸口服治疗,思密达治疗组应用思密达保留灌肠联合5-氨基水杨酸口服治疗,对照组采用5-氨基水杨酸口服治疗。结果瑞巴派特灌肠治疗组总有效率90.69%,明显高于思密达治疗组(总有效率82.5%)及对照组(总有效率68.88%,P<0.05)。结论瑞巴派特保留灌肠联合5-氨基水杨酸口服对溃疡性结肠炎的疗效优于思密达灌肠治疗及传统治疗。Objective The aim of the present study was to assess the clinical efficacy and safety of rebamipide enema therapy associated with 5-aminosalicylic acid in ulcer rative colitis（UC） patients.Methods 128 patients with the active UC were separately treated with rectal administration of rebamipide,or dioctahedral smectite twice a day for 2 weeks,or oral administration of 5-aminosalicylic acid fourth a day for 2 weeks.Results At 2 weeks,90.69% patients with Rebamipide enema therapy achieved clinical remission,which is significantly higher than dioctahedral smectite treatment group（82.5%） and 5-aminosalicylic acid treatment group（68.88%）.Conclusion Rebamipide enema therapy proved to be safe and useful in patients with the active UC.

关 键 词：瑞巴派特 思密达 溃疡性结肠炎 5-氨基水杨酸 

分 类 号：R574.62[医药卫生—消化系统]